Matthew Galsky Discusses Treatment for Lymph Node-Positive Bladder Cancer

The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Follow-up with cholesterol control and audiological assessments is suggested for cisplatin-treated patients with cancer.

In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.

Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.

Stereotactic ablative body radiotherapy in primary renal cell cancer may be a treatment approach with an acceptable adverse effect profile and with minimal impact on renal function.